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At a public hospital in Georgetown, Guyana, 44 patients seeking treatment for symptomatic, slide-conrmed
malaria were given standard chloroquine (CQ) therapy and followed for 28 days. The patients apparently had
pure infections with Plasmodium falciparum (14), P. vivax (13) or P. malariae (one), or mixed infections either of
P. falciparum and P. vivax (17) or of P. falciparum, P. malariae and P. vivax (two). Each received supervised
treatment with 10 mg CQ base/kg on each of days 0 and 1, and 5 mg/kg on day 2. On the day of enrollment
(day 0), the patients complained of fever (100%), headache (100%), malaise (94%), myalgia (79%), nausea
(67%), vertigo (49%) and vomiting (33%). Many (39%) were ill enough to conne themselves to bed. On day 4,
fewer of the subjects complained of fever (15%), headache (15%), malaise (6%), myalgia (21%), nausea (6%),
vertigo (24%) or vomiting (0%) despite the relatively high (>48%) risk of therapeutic failure. The cumulative
incidence of parasitological failure against P. falciparum was 15% at day 4, 33% at day 7 and 48% at day 14. All
of the P. vivax and P. malariae infections cleared before day 4 and none recurred by day 7. Two infections with
P. vivax recurred later (on day 14 or 28) but in the presence of less than adequate, whole-blood concentrations
of CQ plus desethyl-chloroquine (i.e. <100 ng/ml ). Taken together, the results indicate a high risk of therapeutic
failure of CQ against P. falciparum but also indicate that resistance to CQ in P. vivax occurs infrequently in Guyana.

The proliferation of drug-resistant strains
of Plasmodium is complicating the development of national policies for the treatment
of malaria in the developing world. Such
policies often translate to widespread clinical
practice because governments purchase and
Reprint requests to: J. K. Baird.
E-mail: bairdjk@namru2.med.navy.mil; fax: +62 21
424 4507.
© 2002 The Liverpool School of Tropical Medicine
DOI: 10.1179/000349802125001023

distribute the recommended antimalarials at
subsidized costs. These prescribed medicines
often dene consumer preferences in the
private sector. In the developed world, an
array of antimalarials gives health-care providers options suited to individual patients
and the probable sensitivity of the infections
they have acquired. In contrast, patients in
impoverished, rural, endemic areas almost
always receive the drugs recommended
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by the government. Thus, treatment-policy
decisions made by public-health oYcers in
endemic regions directly impact the clinical
management of malaria in the vast majority
of people infected.
In Guyana, the government abandoned
chloroquine (CQ) as rst-line therapy against
P. falciparum in the early 1990s. Complaints
of frequent therapeutic failure from doctors
prompted the decision to adopt the combination of quinine and pyrimethamine–
sulfadoxine as rst-line therapy. Recommended quinine therapy requires three doses
daily for 7 days. The drug causes ringing in
the ears of most of those treated, as well as
vertigo and nausea. It is poorly tolerated and
inadequate compliance with unsupervised
therapy almost certainly occurs regularly.
The risk of recurrent parasitaemia as a consequence of poor compliance with quinine
must be weighed against that attributable
to resistance to CQ. Reliable data characterizing the therapeutic response to CQ
should drive treatment-policy decisions on
alternative therapeutic strategies.
Phillips et al. (1996) described a P. vivax
infection that had been acquired in Guyana
but failed to respond to CQ therapy. As
this case was reported at a time when CQ
remained the rst-line drug for P. vivax
malaria in Guyana, it led to a review of the
national policy for the treatment of P. vivax
and the present trial of the CQ treatment of
P. vivax. As no recent data from Guyana
adequately described the therapeutic response
of local P. falciparum infections to CQ, such
infections were also investigated. The treatment policies for uncomplicated, P. falciparum
and P. vivax malaria in Guyana, where malaria
has become increasingly prevalent since
the 1970s, were retrospectively evaluated.
The study was based in Georgetown, on the
northern coast, where malaria was virtually
eradicated in the 1950s by spraying with
DDT and the distribution of ‘chloroquinized’ salt (Giglioli, 1951; Giglioli et al.,
1976). Malaria on the northern coast remains
relatively rare (Rambajan, 1994) and virtually
all the cases seen in Georgetown are in

adults who are either local residents who
have recently visited the ‘frontier’ interior
or residents of the interior who are visiting
Georgetown.

SUBJECTS AND METHODS
Study Site and Subjects
A treatment trial was initiated in September
1998 using the fever clinic at Georgetown
Public Hospital in Georgetown, Guyana.
This clinic served as a referral centre for
patients suspected of having malaria. The
clinic typically processed 30–50 patients/
day, and 30%–50% of these usually proved
slide-positive for P. falciparum or P. vivax
malaria (with approximately twice as many
P. falciparum infections as P. vivax). Thick
bloodsmears were stained with Giemsa and
screened, under oil immersion at ×1000,
by Ministry of Health microscopists in the
clinic. Only patients with uncomplicated,
slide-proven malaria were screened for enrollment in the trial; those with severe or complicated malaria were referred for admission
to the hospital. Eligible volunteers were at
least 5 years old and agreed to remain in the
vicinity of Georgetown during the 28 days
of post-treatment follow-up. The requirement to remain available during follow-up
caused the majority of the otherwise eligible
subjects to decline to participate. Informed
consent was provided in accordance with
U.S. Navy regulations governing the use
of human subjects in medical research
(SECNAVINST 3900.39B), and as approved
by sanctioned committees for the protection
of human subjects at the Ministry of Health
in Guyana, and the Naval Medical Research
Center in Bethesda, Maryland. Subjects
were examined by a physician and submitted
to venipuncture for collection of 12-ml
samples of whole blood. These samples were
used for the cryopreservation of parasites,
the nested PCR of small-subunit ribosomal
RNA (ssrRNA) for conrmation of diagnosis
(see below), and routine tests for deciency in
glucose-6-phosphate dehydrogenase (G6PD).
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Conrmation of Screening Diagnosis
The screening diagnoses based on the examination of Giemsa-stained thick bloodsmears
were later checked in the laboratory using
blood samples collected at enrollment. Conrmation included examination of Giemsastained thin bloodsmears (for all 49 subjects
enrolled) and a PCR-based assay for the
18srRNA gene (for the 30 samples identied
under the microscope as positive for P. vivax).
For the assay, DNA was extracted, from
blood samples spotted onto FTA® gene
cards (Life Technologies, Rockville, MD),
using a Chelex method (Kain and Lanar,
1991). The DNA was then subjected to two
rounds of PCR using the primers and amplication conditions described by Snounou
et al. (1993). In brief, the rst round of PCR
employed two Plasmodium-specic primers
to amplify the DNA of any Plasmodium sp.
present. In the second round, aliquots of
product from the rst round were placed
into four separate reaction vessels, each containing species-specic primers for unique
18srRNA sequences (Snounou et al., 1993).
In a slight deviation from the published procedure, the rst and second rounds of PCR
were run for 30 and 40 cycles, respectively.
The assays were performed in a 96-well
format that included genomic DNA from
P. falciparum and P. vivax (in distilled water)
as positive controls. Electrophoresis of each
of the nested products of the second round
of PCR was performed in gels of either
3% NuSieve agarose (FMC BioProducts,
Rockland, ME) or 2% SeaKem agarose
(FMC BioProducts). The gels were stained
with ethidium bromide.

Treatment
As part of the enrollment procedure on day 0,
each subject was given uncoated tablets of
chloroquine phosphate (ResochinTM ; Bayer,
Leverkusen, Germany) in the clinic, at a
dose 10 mg base/kg bodyweight. Each subject was watched for 30 min after treatment
and dosing was repeated if vomiting occurred.
The next day a member of the research team
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administered another 10 mg/kg in the subject’s home or workplace. A nal dose, of
5 mg/kg, was likewise administered on the
following day.
HPLC was used to estimate CQ concentrations in whole-blood samples from subjects with suspected CQ-resistant P. vivax
(Baird et al., 1997b).

Follow-up
Smears were prepared of blood samples
collected from the subjects on each of days
0–6, 11, 14, 18, 21 and 28 (for those
infected with P. falciparum) or on days 0,
2, 4, 7, 11, 14, 18, 21 and 28 (for those
infected with P. vivax). The level of any
parasitaemia ( parasites/ml) was estimated by
counting parasites against 200 leucocytes,
on the thick smear, and multiplying the count
by 40 (assuming each subject had 8000
leucocytes/ml). A member of the research
team visited each subject at his or her home
or workplace to collect each post-enrollment
sample and check on the subject’s general
health. Subjects complaining of illness were
brought to the clinic for prompt evaluation
by the physician on the research team.
Subjects with slide-conrmed parasitaemia
after day 3 received alternative therapy with
quinine and pyrimethamine–sulfadoxine.
For subjects without recurrent parasitaemia,
follow-up ended on day 28.

Statistical Analysis
Life tables were used to estimate the risks
of CQ therapeutic failure for P. falciparum
and P. vivax (Baird et al., 1997a). Recurrent
parasitaemia was taken as evidence of therapeutic failure, regardless of clinical signs and
symptoms. Rescue therapy prompted by
an inter-current parasitaemia (i.e. with a
Plasmodium sp. diVerent to that observed on
day 0) constituted a loss to follow-up. Mixed
infections contributed to the analysis of each
species. The rationale for interpreting the
in-vivo test of CQ resistance in P. vivax was
described by Baird et al. (1997a).
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RESULTS
Subjects
Table 1 summarizes the demographic and
parasitological characteristics of the study
population. Overall, 49 subjects, all but nine
of them male, were enrolled. Although
children were eligible, only one child (a girl
with P. falciparum) was enrolled. None of
the subjects had G6PD deciency. The
results of the thin-smear examinations and
PCR-based assays indicated that, at enrollment, the subjects had pure infections with
Plasmodium falciparum (14), P. vivax (13)
or P. malariae (one), or mixed infections
either of P. falciparum and P. vivax (17) or
of P. falciparum, P. malariae and P. vivax
(two).
Diagnosis
Comparison of the results of subsequent
examinations of thick and thin bloodsmears
and of the PCR-based assay with those of
the screening diagnosis demonstrated shortcomings in the initial thick-smear screening as the primary instrument of diagnosis
(Table 2). In brief, many (62%) of the 26
infections initially considered to be solely
of P. vivax were found to be mixtures of
P. vivax and P. falciparum. Five infections
initially identied as solely of P. vivax and
showing nested-PCR results consistent with
P. vivax (or a mixture of P. vivax and
P. falciparum) presented morphological characteristics considered incompatible with a
microscopical diagnosis of P. vivax. These
infections showed: pigmented trophozoites;
TABLE 1.

schizonts containing six to 14 merozoites
each; variation in the sizes of the infected
erythrocytes, from smaller to larger than
normal; and bizarre, grossly enlarged erythrocytes (with diameters two or three times those
of the uninfected erythrocytes), each containing a multinucleated form of the parasite. For these infections, the PCR-based
diagnosis of P. vivax was taken to be correct
for the purpose of reporting therapeutic
responses to CQ, and the presentation of
results in this report reects this approach.
Wherever discrepancies occurred between the
thin-smear-based diagnosis and the results
of the nested-PCR analysis, the latter were
assumed to be correct when estimating the
risks of therapeutic failure.

Responses to Treatment
Plasmodium falciparum
Six of the 33 subjects recorded as P. falciparum
infections were lost to follow-up (i.e. they
could not be located at home or work) prior
to day 4, but all of the remaining 27 reached
the end-point of recurrent parasitaemia or
day 28 of follow-up. Of these 27 subjects
(see Table 3), four failed to clear their
P. falciparum parasitaemias by day 4 and
were therefore given alternative treatment.
Another 11 subjects cleared their parasitaemias by day 4 but had to be given
alternative treatment because of recurrent
P. falciparum parasitaemia by day 7 (ve),
between days 8 and 14 (four) or on days 17
(one) or 28 (one). Thirteen of the 27 subjects diagnosed with P. falciparum did not have

Demographic and parasitological characteristics of the study population
No. of subjects

Initial diagnosis
P. falciparum malaria
P. vivax malaria
P. malariae malaria

Studied

Male

Female

With mixed
infection

Mean age and
(range) (years)

Mean day-0 parasitaemia
and (range)* ( parasites/ml)

33
32
3

27
25
3

6
7
0

19
19
2

26 (10–63)
31 (18–55)
38 (33–42)

7380 (40–92,240)
3980 (120–17,120)
3880†

* Mean counts exclude the mixed infections.
† The count for the sole mono-infection.
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TABLE 2. Comparison of the results of the screening, based on thick bloodsmears, with those of the subsequent examination
of thin smears and the PCR-based assay, for all the subjects who were identied as having Plasmodium vivax infection
in the initial screening and then investigated by the PCR-based assay*
Results of:
Thick-smear screening
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.

falciparum+P. vivax
falciparum+P. vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
falciparum+P. vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax

Thin-smear examination
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. falciparum+P. vivax
P. vivax
P. malariae
P. falciparum+P. malariae
P. vivax+P. malariae
Indeterminate
Indeterminate
Indeterminate
Indeterminate
P. falciparum+indeterminate

Nested PCR
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.
P.

vivax
vivax
vivax
vivax
vivax
vivax
vivax
vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum+P. vivax
falciparum
malariae
vivax+P. malariae+P. falciparum
vivax+P. malariae+P. falciparum
vivax
vivax
vivax
falciparum+P. vivax
falciparum+P. vivax

Parasitaemia†
(trophozoites/ml)
15,360
120
6080
12,640
1280
640
1840
11,200
1920
1920
9120
4800
640
4000
720
160
560
1280
320
1120
1520
3880
560
4960
920
2880
6560
17,200
9760

* No PCR data were produced for another ve subjects identied as having pure P. vivax infections (two) or
mixed P. vivax/P. falciparum infections (three) at the initial screening.
† Estimated from counts on the thick bloodsmears.

recurrent parasitaemia during the 28 days
of follow-up. None of the 27 subjects with
P. falciparum infection at enrollment developed
an inter-current P. vivax parasitaemia. The
Figure illustrates the cumulative incidence of
P. falciparum after the standard CQ therapy.
The risk of the therapeutic failure of CQ
against P. falciparum in Guyana was estimated at 33% by day 7 and 48% by day 14.
Of the subjects found to be infected with
P. falciparum at enrollment, >75% reported
relief from physical complaints within 4 days
of their rst dose of CQ (Table 4). Among
those subjects who cleared their P. falciparum

parasitaemias by day 4, >90% were free of
all physical complaints except arthralgia and
dizziness by day 4.

Plasmodium vivax
Three of the 32 subjects initially infected
with P. vivax were lost to follow-up before
day 4 (Table 3). Another eight, all with
mixed infections at enrollment, were withdrawn because they had to be treated for
recurrent P. falciparum parasitaemia by day 14.
Although two more subjects had (slide- and
nested-PCR-conrmed) recurrent P. vivax
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TABLE 3.

Life tables for the therapeutic failure of chloroquine against Plasmodium falciparum and P. vivax*

Parasite
Plasmodium falciparum

Plasmodium vivax

Interval
(day)

N

i

w

IR

CI

0†
4
7
11
14
18
21
28
0†
4
7
11
14
18
21
28

33
27
23
18
16
14
13
13
32
31
29
27
26
22
22
22

0
4
5
2
2
1
0
1
0
0
0
0
1
0
0
1

6
0
0
0
0
0
0
0
3
2
2
1
3
0
0
0

0
0.1482
0.2174
0.1111
0.125
0.0714
0
0.0769
0
0
0
0
0.0408
0
0
0.0454

0
0.1482
0.3334
0.4075
0.4816
0.5186
0.5186
0.5556
0
0
0
0
0.0408
0.0408
0.0408
0.0844

* N is the number of subjects at risk in the interval, I the number of incident cases of therapeutic failure, w the
number of withdrawals due to loss to follow-up or parasitaemia with another species, IR the interval risk
{i/[N(w/2)]}, and CI is the cumulative incidence {1[(1IR )×(1CI )] } in which IR is the current
a
b
a
interval risk and CI the cumulative incidence of the prior interval.
b
† At enrollment.
TABLE 4.
infections

Resolution of clinical complaints following chloroquine treatment of the subjects with Plasmodium falciparum

Day-4 frequency (%) among:
Complaint
Sick
Febrile
Headache
Malaise
Muscle ache
Joint ache
Nausea
Dizziness
Vomiting
Diarrhoea
Disturbed vision
Conned to home

Day-0 frequency
(%)

All subjects

Those aparasitaemic on day 4

100
100
100
94
79
76
67
49
33
21
12
39

18
15
15
6
21
24
6
24
0
10
12
12

9
9
6
3
9
15
3
15
0
10
9
6

parasitaemia on day 14 or 28, each had
a whole-blood concentration of CQ plus
desethyl-chloroquine on the day of recurrence (74 and 0 ng/ml) that was below the
minimum eVective concentration for P. vivax.
These two cases of recurrent parasitaemia
were therefore considered consistent with
CQ-sensitive P. vivax.

DISCUSSION
This report documents a substantial risk of
therapeutic failure of CQ among a small
sample of subjects infected with P. falciparum
in Guyana, South America. The sample only
represented a small proportion of the patients
reporting to the enrollment site because
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FIG. Cumulative risk of post-chloroquine, recurrent, Plasmodium falciparum parasitaemia in Guyana.

most such patients had been infected in the
interior of the country while working for a
living and wished to return to the interior as
quickly as possible. That most of the subjects
were adult males is probably evidence that
travel to (or residence in) the forested interior
is a dominant risk factor for infection among
patients seeking treatment in Georgetown;
infection among populations resident in
the endemic interior occurs across all ages
(Rambajan, 1994). The present subjects
represented people who had incidentally
planned on remaining in Georgetown for at
least 28 days, usually for reasons related to
family activities. It seems unlikely that this
produced a sample bias with respect to risk
of therapeutic failure.
Nearly half (48%) of the P. falciparum
infections recurred within 14 days of the
rst dose of CQ, with relatively few recurrences after day 14 (the 28-day cumulative

incidence was 55%). Plasmodium falciparum
in Guyana appears polarized with respect
to CQ susceptibility, with resistant and
susceptible populations mixed in roughly
equal proportions. Approximately one half
of the infections recrudesced within 14 days,
whereas the other half appeared completely
susceptible to CQ. This unusual pattern may
be a product of the termination, in the early
1990s, of the use of CQ as rst-line therapy
against P. falciparum in Guyana, which presumably diminished the survival advantage
of resistance to the drug. In the absence of
baseline data, however, this interpretation
represents just one of several possible
explanations.
The small sample of P. vivax evaluated in
this study failed to reveal any therapeutic
failure attributable to resistance to CQ.
Among the 32 subjects with P. vivax, only
two had recurrent P. vivax parasitaemia
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during 28 days follow-up, and both of these
had inadequate blood concentrations of CQ
plus desethyl-chloroquine (<100 ng/ml) at
the time of the recurrence. If this sample
were representative of P. vivax in Guyana,
the risk of resistance to CQ would be less
than one in 30 infections. Despite convincing evidence that CQ-resistant P. vivax
occurs in Guyana (Phillips et al., 1996), the
results of the present (albeit small-scale)
study indicate that, during late 1998, the
risk of therapeutic failure because of such
resistance was <5%.
The primary therapy currently recommended for uncomplicated, P. falciparum
malaria in Guyana is 7 days of quinine and
a single dose of pyrimethamine–sulfadoxine.
This was the regimen provided to the present
subjects who failed to clear their infections
with CQ. Unfortunately, many of these
patients returned to the clinic within 2 weeks
of their rst dose of quinine, all with
recurrent P. falciparum parasitaemia (data
not shown). As failure to comply with the
unsupervised regimen of quinine was the rule
among these subjects, this therapeutic strategy
suVers obvious shortcomings. However, there
are few if any practical alternatives available
to the local Ministry of Health. Neither the
government nor most residents of Guyana
possess the economic wherewithal to purchase highly eVective and well-tolerated
antimalarials such as Lariam® (meoquine)
or Malarone® (atovaquone–proguanil).
Therapies involving artemisinin derivatives
are not available. Uncomplicated, P. falciparum
malaria in Guyana appears to receive
inadequate therapy often.
Despite the high risk of parasitological
failure with CQ against P. falciparum, most
subjects infected with this parasite experienced almost complete clinical recovery within
4 days of their rst dose of the drug (Table 4).
This was especially true among those
who managed to clear their parasitaemias by
day 4. Most experienced rapid and substantial relief from illness despite the high
risk of recurrence with symptoms (13 of
15 complained of being ill at the time of

their recurrent parasitaemias). This nding
corroborates similar observations in Africa
and South–east Asia (HoVman et al., 1983;
Khoromana et al., 1986). However, CQ
therapy in the face of even a relatively
modest resistance has been associated with
increased risk of malaria-attributable death
(Zucker et al., 1996; Trape et al., 1998).
The training of Ethiopian mothers to treat
their young children with CQ reduced
mortality in the children by 40% (Kidane
and Morrow, 2000). In this case, ‘selftreatment’ with CQ was obviously better
than no treatment, but eVective alternative
therapy would avoid the unnecessary risk
of death resulting from parasitic resistance
to CQ. The ‘self-treating’ poor may not
appreciate such risk after clinical recovery,
and they may fail to understand that CQ
therapy may exacerbate the transmission
of malaria by creating asymptomatic but
infectious carriers. An eVective alternative
therapy that costs as little as CQ but has an
equally good safety and tolerance prole
would be required to undermine the economic forces that drive CQ use in the face
of resistance.
The data shown in Table 2 demonstrate
considerable inaccuracy in the initial screening diagnosis based on the examination
of thick bloodsmears. Given the high risk of
CQ-resistant P. falciparum and the continued use of CQ as the rst-line treatment
for P. vivax infection in Guyana, the large
proportion of mixed P. vivax/P. falciparum
infections misdiagnosed as pure P. vivax
infections (62%) is worrisome. Many individuals infected with P. falciparum must be
receiving only CQ therapy on the basis of a
P. vivax diagnosis at screening. The clinic
where this study was conducted employed
two or three, full-time microscopists who
essentially worked non-stop during the hours
of the clinic’s operation, to keep up with
the demand. The addition of thin-smear
reading, to increase the chances of detecting
P. falciparum in mixed infections, would very
substantially increase the workload and, like
PCR-based assays, would not be practical
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with the available resources. The solution
to the problems of poor compliance with
quinine and poor diVerentiation of species
by thick-smear-based diagnosis may be a
single, well tolerated alternative therapy
that is eVective against both P. falciparum
and P. vivax. Combined therapies merit
exploration as possible solutions to this
problem. Furthermore, administering 45 mg
primaquine weekly for 8 weeks would not
only achieve eVective transmission-blocking
but also kill the liver stages of P. vivax. A
means of assuring compliance to this regimen
would substantially improve protection of the
gains made against malaria on the coast of
Guyana.
The northern coast of Guyana, where
>75% of the country’s population of about
700,000 live, has been largely free of malaria
since a campaign of DDT spraying and
distribution of ‘chloroquinized’ salt during
the 1950s and 1960s (Giglioli et al., 1976;
Rambajan, 1994). Nonetheless, the region
remains receptive to endemic malaria. The
primary vector, Anopheles darlingi, has demonstrated the ability to re-establish itself on the
coast and trigger outbreaks from infections
introduced by travellers from the interior
(Rambajan, 1987, 1988, 1994). Although
An. darlingi (an eYcient vector) remains rare
in the coastal region, the ineYcient vector
An. aquasalis occurs in abundance (S. Rawlins,
unpubl. obs.). The ease of human travel
between the malaria-free coastal region and
the malaria-endemic interior constitutes an
obvious threat, and one that is amplied by
the apparent inadequacy of the available
therapy. At least three of the present subjects
apparently acquired their infections on the
outskirts of Georgetown (data not shown).
In the absence of eVective, unsupervised
therapy for malaria or a resumed application of
residual insecticides, endemic, CQ-resistant,
P. falciparum malaria threatens to reclaim
the coastal region of Guyana.
In conclusion, the high risk of therapeutic failure of CQ against uncomplicated,
P. falciparum malaria in Guyana supports
the Ministry of Health’s earlier abandon-
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ment of CQ as the rst-line drug for such
disease. At the time of the present study,
CQ apparently remained eVective for most
P. vivax acquired in Guyana, but other
evidence of CQ resistance in this species
merits surveillance of the problem. In view
of the high frequency of mixed infections of
P. falciparum and P. vivax not detected
by routine diagnostic procedures, an ideal
therapeutic regimen would be eVective against
both species. Poor compliance with quinine
therapy for P. falciparum and the high risk of
undiagnosed P. falciparum mixed with P. vivax
being treated with CQ alone merits reconsideration of the national treatment policy.
Re-introduced endemic malaria threatens
the heavily populated coastal region of
Guyana and addressing the threat requires
eVective treatment strategies. A Plasmodium
sp. in Guyana with an ssrRNA gene
apparently indistinguishable from P. vivax,
but having consistent morphological characteristics incompatible with that species, was
identied.

acknowledgements. The study was supported by Veteran’s Administration grant
(98-FRS-0273) to J.K.B. and S.L.H.,
STEP F, 6.2 and 6.3 of the Military
Infectious Diseases Research Program, the
Department of Defense Global Emerging
Infections System, and the Pan American
Health Organization (PAHO) in Washington,
DC. The views and opinions expressed
herein are those of the authors and do not
purport to reect or represent those of
the U.S. Navy or the U.S. Department of
Defense. The authors gratefully acknowledge
the assistance and support of Dr R. Gusmao
(PAHO, Washington) and V. Brown (PAHO,
Georgetown). The outstanding eVorts of the
Ministry of Health team in Georgetown
— especially L. Seelochan, O. Laine,
V. MacKenzie, E. Camilla and their
colleagues in the Vector Control Unit —
made this work possible. The United States
Embassy in Georgetown provided logistical
and administrative support to this eVort. CQ

348

BAIRD ET AL.

concentrations in key blood samples were
graciously measured by Dr D. J. FryauV
and B. Leksana at the U.S. Naval Medical
Research Unit #2 in Jakarta, Indonesia.

REFERENCES
Baird, J. K., Leksana, B., Masbar, S., FryauV, D. J.,
Sutanihardja, M. A., Suradi, Wignall, F. S. &
HoVman, S. L. (1997a). Diagnosis of resistance to
chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. American
Journal of Tropical Medicine and Hygiene, 56,
621–626.
Baird, J. K., Wiady, I., FryauV, D. J.,
Sutanihardja, M. A., Leksana, B., Widjaya, H.,
Kysdarmanto & Subianto, B. (1997b). In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia.
American Journal of Tropical Medicine and Hygiene,
56, 627–631.
Giglioli, G. (1951). Eradication of Anopheles darlingi
from the inhabited areas of British Guiana by residual
spraying. Journal of the National Malaria Society, 10,
142–161.
Giglioli, G., Chen, W., Marchant, D. E. & Howell, P.
(1976). Malaria eradication in Guyana. Tropical
Doctor, 6, 126–132.
HoVman, S. L., Masbar, S., Hussein, P. R.,
Soewarta, A., Harun, S., Marwoto, H. A.,
Campbell, J. R., Smrkovski, L., Purnomo & Wiady, I.
(1983). Absence of malaria mortality in villagers with
chloroquine-resistant Plasmodium falciparum treated
with chloroquine. Transactions of the Royal Society of
Tropical Medicine and Hygiene, 78, 175–178.
Kain, K. C. & Lanar, D. E. (1991). Determination of
genetic variation within Plasmodium falciparum by
using enzymatically amplied DNA from lter paper
disks impregnated with whole blood. Journal of
Clinical Microbiology, 29, 1171–1174.

Khoromana, C. O., Campbell, C. C., Wirima, J. J.
& Heynmann, D. L. (1986). In vivo eYcacy of
chloroquine treatment for Plasmodium falciparum in
Malawian children under ve years of age. American
Journal of Tropical Medicine and Hygiene, 35,
465–471.
Kidane, G. & Morrow, R. H. (2000). Teaching mothers
to provide home treatment of malaria Tigray,
Ethiopia: a randomized trial. Lancet, 356, 550–555.
Phillips, E. J., Keystone, J. S. & Kain, K. C. (1996).
Failure of combined chloroquine and high dose
primaquine therapy for Plasmodium vivax acquired in
Guyana, South America. Clinical Infectious Diseases,
23, 1171–1173.
Rambajan, I. (1987). An annotated checklist of the
Anopheles of Guyana, South America. Mosquito
Systematics, 19, 146–161.
Rambajan, I. (1988). Reappearance of unprecedented
falciparum malaria 28 years after the last case in the
Cuyuni-Mazaruni-Potaro, Guyana, South America.
Tropical and Geographical Medicine, 40, 269–271.
Rambajan, I. (1994). Highly prevalent falciparum
malaria in northwest Guyana: its development history
and control problems. Bulletin of the Pan American
Health Organization, 28, 193–201.
Snounou, G., Viriyakosol, S., Zhu, X. P., Jarra, W.,
Pinheiro, L., do Rosario, V. E., Thaithong, S. &
Brown, K. N. (1993). High sensitivity of detection
of human malaria parasites by the use of nested polymerase chain reaction. Molecular and Biochemical
Parasitology, 61, 315–320.
Trape, J. F., Pison, G., Preziosi, M. P., Enel, C.,
Desgrees, L. A., Delaunay, V., Samb, B., Lagarde, E.,
Molez, J. F. & Simondon, F. (1998). Impact of
chloroquine resistance on malaria mortality. Comptes
Rendus de l’Académie des Sciences. Series 3, Sciences de
la Vie, 321, 689–697.
Zucker, J. R., Lackritz, E. M., Ruebush II, T. K.,
Hightower, A. W., Adungosi, J. E., Were, J. B.,
Metchock, B., Patrick, E. & Campbell, C. C. (1996).
Childhood mortality during and after hospitalization
in western Kenya: eVect of malaria treatment regimens.
American Journal of Tropical Medicine and Hygiene,
55, 655–660.

